Cancer Patients Experience Longer Survival In Community Oncology Settings

Flatiron Health and Community Oncology Alliance partner to deliver first comprehensive, real-world assessment of care in community oncology, affirming the high-quality care delivered across community practices.

Patients diagnosed with metastatic breast cancer and non-small cell lung cancer had longer survival compared to national benchmarks when treated in independent community oncology practices, according to a new study commissioned by the Community Oncology Alliance (COA) and conducted by Flatiron Health. The research supports independent community oncologists' ability to deliver high-quality outcomes for the majority of U.S. patients with cancer who receive care in community oncology settings.

The study shows that median survival for patients diagnosed with breast cancer that spread to other organs and treated at a Flatiron Health Research Network (FHRN) community oncology practice exceeded national benchmarks by eight months. Median survival for those with non-small cell lung cancer- the most common lung cancer- treated at FHRN community oncology practices exceeded national benchmarks by two month. Survival rates after one, three, and five years were consistently higher for patients treated at community oncology practices within the FHRN relative to national benchmarks.

• Click to read the full press release
• Click to read the full study on quality of care in community oncology